Skip to main content

Table 3 Pearson Phi correlations between PtGA and Pain, HAQ-DI, and FACIT-F outcomes at month 3 in csDMARD-IR patients

From: Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

    N Correlation coefficient P value
a) Correlation with LDA (PtGA VAS score ≤ 20 mm)
Mild Pain (VAS score ≤ 20 mm)
 Tofacitinib 5 mg BID + csDMARDs   695 0.74 < 0.0001
 Placebo + csDMARDs   366 0.73 < 0.0001
Moderate Pain improvement (≥ 30% decrease from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.42 < 0.0001
 Placebo + csDMARDs   365 0.45 < 0.0001
Substantial Pain improvement (≥ 50% decrease from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.55 < 0.0001
 Placebo + csDMARDs   365 0.58 < 0.0001
HAQ-DI score ≥ normative value (≤ 0.25)
 Tofacitinib 5 mg BID + csDMARDs   695 0.28 < 0.0001
 Placebo + csDMARDs   366 0.24 < 0.0001
HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline)
 Tofacitinib 5 mg BID + csDMARDs   693 0.18 < 0.0001
 Placebo + csDMARDs   364 0.14 0.0064
FACIT-F score ≥ normative value (≥ 43.5)
 Tofacitinib 5 mg BID + csDMARDs   694 0.35 < 0.0001
 Placebo + csDMARDs   365 0.29 < 0.0001
FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline)
 Tofacitinib 5 mg BID + csDMARDs   693 0.13 0.0004
 Placebo + csDMARDs   363 0.11 0.0413
b) Correlation with moderate PtGA improvement (≥ 30% decrease from baseline)
Mild Pain (VAS score ≤ 20 mm)
 Tofacitinib 5 mg BID + csDMARDs   694 0.42 < 0.0001
 Placebo + csDMARDs   365 0.42 < 0.0001
Moderate Pain improvement (≥ 30% decrease from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.64 < 0.0001
 Placebo + csDMARDs   365 0.55 < 0.0001
Substantial Pain improvement (≥ 50% decrease from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.56 < 0.0001
 Placebo + csDMARDs   365 0.55 < 0.0001
HAQ-DI score ≥ normative value (≤ 0.25)
 Tofacitinib 5 mg BID + csDMARDs   694 0.13 0.0006
 Placebo + csDMARDs   365 0.16 0.0029
HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.30 < 0.0001
 Placebo + csDMARDs   364 0.30 < 0.0001
FACIT-F score ≥ normative value (≥ 43.5)
 Tofacitinib 5 mg BID + csDMARDs   693 0.17 < 0.0001
 Placebo + csDMARDs   364 0.18 0.0008
FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.24 < 0.0001
 Placebo + csDMARDs   363 0.26 <  0.0001
c) Correlation with substantial PtGA improvement (≥ 50% decrease from baseline)
Mild Pain (VAS score ≤ 20 mm)
 Tofacitinib 5 mg BID + csDMARDs   694 0.55 < 0.0001
 Placebo + csDMARDs   365 0.50 < 0.0001
Moderate Pain improvement (≥ 30% decrease from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.59 < 0.0001
 Placebo + csDMARDs   365 0.51 < 0.0001
Substantial Pain improvement (≥ 50% decrease from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.68 < 0.0001
 Placebo + csDMARDs   365 0.70 < 0.0001
HAQ-DI score ≥ normative value (≤ 0.25)
 Tofacitinib 5 mg BID + csDMARDs   694 0.18 < 0.0001
 Placebo + csDMARDs   365 0.13 0.0126
HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.29 < 0.0001
 Placebo + csDMARDs   364 0.26 < 0.0001
FACIT-F score ≥ normative value (≥ 43.5)
 Tofacitinib 5 mg BID + csDMARDs   693 0.23 < 0.0001
 Placebo + csDMARDs   364 0.20 0.0001
FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline)
 Tofacitinib 5 mg BID + csDMARDs   692 0.26 < 0.0001
 Placebo + csDMARDs   363 0.23 < 0.0001
  1. Generally, correlation coefficient values around 0.3, 0.5, and 0.7 are considered as weak, moderate, and strong positive linear correlations, respectively
  2. Abbreviations: BID twice daily, csDMARD conventional synthetic disease-modifying antirheumatic drug, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-Disability Index, IR inadequate responder, LDA low disease activity, MCID minimum clinically important difference, PtGA Patient Global Assessment of Disease Activity, VAS Visual Analog Scale